Precision BioSciences (DTIL) investor relations material

Executive summary

• Advanced in vivo gene editing therapies for genetic and infectious diseases using the ARCUS platform, with lead programs PBGENE-HBV for hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, achieving key regulatory and clinical milestones in Q1 2026.

• PBGENE-HBV progressed in global clinical trials, including the ELIMINATE-B trial, with expanded dosing cohorts and European trial expansion; new clinical data expected in 2026.

• PBGENE-DMD received FDA Fast Track and Orphan Drug designations, began enrolling patients in a Phase 1/2 trial, and is eligible for a Priority Review Voucher.

• Partnered programs (iECURE’s ECUR-506 and Imugene’s Azer-Cel) advanced, with milestone payments received and upcoming data presentations.

• Achieved a $7.5 million milestone payment from TG Therapeutics for a partnered ex vivo program.

Financial highlights

• Q1 2026 revenue was $10.8 million, up from less than $0.1 million in Q1 2025, driven by milestone and license payments.

• Net loss for Q1 2026 was $18.4 million ($0.75 per share), improved from $20.6 million ($2.21 per share) in Q1 2025.

• Operating expenses decreased to $19.9 million from $22.1 million year-over-year, with R&D at $13.1 million and G&A at $6.8 million.

• Cash, cash equivalents, and restricted cash totaled $125.8 million as of March 31, 2026, supporting operations through 2028.

• Accumulated deficit reached $546.6 million as of March 31, 2026.

Outlook and guidance

• Cash runway, fiscal discipline, and ATM facility expected to fund operations and key data milestones for PBGENE-HBV and PBGENE-DMD through 2028.

• Additional clinical data from lead and partnered programs anticipated at major medical conferences throughout 2026.

• Additional capital may be required if assumptions change or new opportunities arise.